Recent years have seen a number of regulatory approvals for immune oncology or immunotherapies based on their ability to enhance antitumor immune responses.
| INTRODUCTION
The development of effective strategies to activate the immune system for the treatment of cancer has become a major focus of research in cancer therapeutics. Indeed, remarkable progress has been made in cancer immunotherapies as typically exemplified by cancer-targeting monoclonal antibody treatment, immune checkpoint blockade, cancer vaccine, and chimeric antigen receptor T-cell therapy. 1, 2 However, these therapies are not always effective, leaving a number of patients in need of alternatives. In this context, several major steps may be needed for the effective control of cancer by the immune system, and these include activation of innate immune responses necessary for activation of innate antitumor responses and priming of anticancer T-cell responses. 3, 4 The innate immune system constitutes the first line of defense against invading pathogens. Recognition by one of several classes of PRR of PAMP results in immune activation. 5 Among PRR, STING is a particular focus of attention in antitumor immune responses. 6 STING is a PRR for CDN and also functions as an adaptor protein for multiple cytosolic receptors of double-stranded DNA. 7 The hallmark of STING pathway activation is the induction of type I IFN production, [8] [9] [10] and there is good evidence that type I IFN exert antitumor activities. 11 Therefore, the search for drugs that activate the STING-type I IFN axis has been an attractive area for cancer immunotherapy. 7 To date, two synthetic small compounds, DMXAA and CMA, have been developed as STING agonists inhibiting tumor development. 12, 13 Both compounds induce type I IFN production in antigenpresenting cells and giving these compounds to mice suppresses tumor growth. 14, 15 However, DMXAA and CMA function only in mouse cells, not in human cells. 12, 13 In addition to these small compounds, ML RR-S2, an analog of CDN, has been synthesized as another STING agonist. 14, 16 Although ML RR-S2 is effective both in mouse and in human cells and suppresses tumor growth in mice, type I IFN induction is restricted to antigen-presenting cells and not to cancer cells. 14 As type I IFN often exert antitumor activities by directly acting on cancer cells, 17 it would be interesting to search drugs that induce type I IFN in cancer cells.
In the present study, we found that a synthetic small compound, SINCRO, activates the STING pathway in mouse and human cells, inducing IFN-β gene expression. In addition, we also show that SINCRO treatment of cancer cells triggers cell death. Interestingly, SINCRO-triggered cytotoxicity is independent of the STING pathway and conventional apoptosis-inducing pathway, suggesting the dual function of SINCRO.
We discuss the potential significance of the discovery and characterization of SINCRO for future drug development for cancer therapy. In some experiments, the cells were stimulated with poly dA:dT (B-DNA) (10 μg/mL) for 9 hours as described previously. 21 Total RNA was extracted from the cells using RNAiso Plus (TaKaRa, Shiga, Japan) and reverse-transcribed into cDNA with PrimeScript RT Reagent Kit with gDNA Eraser (Perfect Real Time) (TaKaRa) according to the manufacturer's instructions. qRT-PCR was carried out as described previously. 23 Expression levels of mouse and human mRNA were normalized to those of Gapdh and GAPDH, respectively. 
| MATERIALS AND METHODS

| Reagents and cells
| Optical characterization of SINCRO
| Statistical analysis
Data were analyzed by two-tailed, unpaired Student's t test. P-value <0.05 was considered significant. | 2689 stimulated B16F1 cells with SINCRO for 6 hours, removed the compound by washing, and then collected the medium from the cells incubated for another 6 hours. When the resulting conditioned medium was mixed with B16F1 cells, IFN-β mRNA was not significantly induced in the B16F1 cells ( Figure S2A ) whereas, in contrast, the mRNA was induced in the B16F1 cells used to prepare the conditioned media ( Figure S2B ). Thus, we surmise that IFN-β was not triggered by SINCRO-mediated release of nucleic acids.
| RESULTS
| SINCRO induces IFN-β expression in cancer cells and immune cells
We next examined subcellular localization of SINCRO using confocal microscopy. First, the absorption and fluorescence properties of SINCRO were determined ( Figure S2C,D) . In B16F1 cells treated with SINCRO, fluorescence associated with SINCRO was mainly detected within the endosome/lysosome of the cells based on colocalization with a LysoTracker cell dye (Molecular Probes) ( Figure S2E ).
Thus, these observations indicate that SINCRO is internalized into cells through the endocytosis pathway. 
|
| SINCRO induces cell death in cancer cells
In addition to immune cell activation, we also considered cytotoxic effects of SINCRO on cancer cells. SINCRO-mediated cytotoxicity against B16F1 cells was analyzed by a MTT cell viability assay and Annexin V/PI staining. As shown in Figure 3A 
| SINCRO induces cell death in a STING-and caspase-independent pathway
To determine the mechanism of SINCRO-mediated cell death, we first examined the involvement of the STING pathway using BMDC Ifnb relative expression Notably, we found that SINCRO treatment of B16F1 cells increased p62 protein expression level, although not significantly affecting the level of an autophagosome marker LC3-I/II ( Figure 4C ).
F I G U R E 2 N-{3-[(1,4′-bipiperidin)-1′-yl]propyl}-6-[4-(4-methylpiperazin-1-yl)phenyl]picolinamide, STING-mediated interferon-inducing and cytotoxic reagent, original (SINCRO) induces STING-dependent interferon (IFN)-β expression. Bone marrow-derived dendritic cells (BMDC
p62 is known to be a substrate of autophagic protein degradation and to be upregulated in response to oxidative stress. 30 In addition, ROS produced during oxidative stress induce caspase-independent cell death. [31] [32] [33] [34] Indeed, SINCRO-induced B16F1 cell death was suppressed, albeit not completely, by treatment with NAC, a ROS scavenger ( Figure S4D ). Thus, SINCRO induces cancer cell death through oxidative stress and other yet unknown mechanism(s), wherein STING and caspases are not involved. shown to play critical roles in the activation of antitumor T-cell responses. [8] [9] [10] Based on these findings, agonists for STING, such as DMXAA, CMA and ML RR-S2, have been developed and found to be effective in several tumor models. [14] [15] [16] A limitation to advancement of some of these molecules for treatment of human malignancy is the lack of cross-reactivity to humans. 12, 13 In the present study, we report that SINCRO is a novel chemical compound that Instead, our results showed that the expression level of an autophagy substrate p62 was elevated by SINCRO treatment despite no downregulation of autophagy ( Figure 4C ). In this context, it has been reported that p62 expression levels are increased during oxidative stress, 30 and oxidative stress is induced by LMP, the release of lysosomal components into the cytosol. 35, 36 As SINCRO accumulates in the endosome/lysosome compartment ( Figure S2E STING, while enhancing cytocidal activity that is more selective to cancer cells.
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